A3 Secondary Metabolites · Depside · Reference metabolite

Atranorin Bioactivity Line

A widely cited lichen compound with repeatedly published bioactivity, included in both of our screening studies. A dependable reference compound and panel anchor for antiproliferative, antioxidant and antimicrobial work.

Book a 30-minute discovery call Request the data package

Evidence: Peer-reviewed 2022 & 2023
Stage: Pilot-ready · licensing open
Indicative: € 4 000 – 22 000negotiable by scope and application

Scientific summary

Atranorin is one of the most frequently studied lichen metabolites and appears in both of our published datasets: the 2022 comparative antioxidant study and the 2023 screening panel, where it was tested for antiproliferative activity in 2D monolayer and 3D spheroid models alongside antimicrobial and DPPH testing.

Role in a screening programme

Its value is as a dependable anchor. Because it has been measured repeatedly across laboratories and assay formats, it lets you calibrate a new panel, compare your own candidates against a known quantity, and detect assay drift between runs.

Applications

Cytotoxicity and antiproliferative screening
Redox modulation studies
Reference standard in multi-compound panels
Antimicrobial screening

Assays & readouts available

2D and 3D spheroid viability
DPPH and superoxide scavenging
In vitro antimicrobial testing
NMR structural confirmation

Specification

Compound class	Didepside (lichen secondary metabolite)
Biological source	Hypogymnia physodes and related species
Evidence status	Published evidence (in vitro), two independent studies
Publications	Elečko J et al., Plants 2022;11(8):1077 · Kello M et al., Plants 2023;12(3):611
Typical pilot	Bioactivity pilot 4–8 weeks
Deliverables	Isolated material, panel data, technical report
Engagement	Feasibility scan · pilot · licensing
Indicative price	€ 4 000 – 22 000, negotiable by scope and application

What happens next

Book a call or send an inquiry. Tell us the target, the application and the timeline.
We answer within three working days — including when the answer is that we cannot help.
NDA before disclosure, if you need one. Tick the box on the form.
Feasibility scan or pilot proposal with a defined scope, deliverable and price.

Book a 30-minute discovery call Send an inquiry

Common questions

How does an engagement start?

With a free 30-minute discovery call. We establish whether there is a fit and what the right next step is. Nothing is committed at that point.

Can we sign an NDA before we describe our project?

Yes. Tick the NDA box on the inquiry form and we arrange it before any disclosure.

Are the prices on this site binding?

No. They are indicative ranges so that you can size a project before contacting us. Final terms are negotiated per scope.

How quickly do you reply?

Every inquiry is acknowledged within one working day and answered by the responsible group leader within three.

What happens if you cannot help?

We say so, early, and where we can we point you to someone who can. A negative feasibility answer delivered quickly is a useful result.

Related in Secondary Metabolites

A1Lead compound

Depside · Umbilicaria hirsuta

Gyrophoric Acid Platform

The best-characterised compound in the portfolio. Published work reports ROS production, apoptosis and modulation of Akt, Erk1/2 and p38 MAPK in HeLa cells, with a validated isolation protocol giving high-purity material.

Evidence: Peer-reviewed 2019 · mechanistic dataset
Stage: Pilot-ready · licensing open
Indicative: € 8 000 – 35 000negotiable by scope and application

View details Discuss this

Depsidone · Hypogymnia physodes

3-Hydroxyphysodic Acid Antioxidant Line

The strongest radical scavenger in our comparative metabolite study — and the comparison was made per mole rather than per unit weight. That distinction matters when you translate a screening result into a formulation dose.

Evidence: Peer-reviewed 2022 · DPPH + superoxide
Stage: Pilot-ready · licensing open
Indicative: € 5 000 – 25 000negotiable by scope and application

View details Discuss this

Depsidone · Hypogymnia physodes

Physodic Acid Bioactivity Line

Present in both of our published panels, with antioxidant and antiproliferative activity reported in 2D and 3D models. A natural comparator when you want to benchmark a candidate against gyrophoric acid within one experimental system.

Evidence: Peer-reviewed 2022 & 2023
Stage: Pilot-ready · licensing open
Indicative: € 5 000 – 25 000negotiable by scope and application

View details Discuss this

Tell us what you are trying to achieve.

A free 30-minute call establishes whether there is a fit and what the right next step is. Every inquiry is acknowledged within one working day and answered by the responsible group leader within three.

Book a 30-minute discovery call Send an inquiry instead